A Phase 3 interventional study of Apomorphine hydrochloride and Placebo in Parkinson's Disease, sponsored by Britannia Pharmaceuticals Ltd.. Completed at 20 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-07-08.
Sponsored by Britannia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing apomorphine in Parkinson Disease — 1 open to participants now, 2 under way, 1 of them phase 3. Apomorphine · Parkinson Disease.
Among the 32 studies testing apomorphine in Parkinson Disease, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 12 in phase 3, and was the 15th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →1 of the 32 studies testing apomorphine in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–89
By country, each count listing its studies:
Apomorphine: first FDA approval 2004 (APOKYN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 14 · Phase 4 5
First in 1999; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 42 across the 32 interventional studies. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 32 have an industry lead sponsor. The 10 most frequent:
Britannia Pharmaceuticals Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Britannia Pharmaceuticals Ltd. has 4 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing apomorphine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical treatment.
The secondary objective of the study was to investigate the safety and tolerability of apomorphine continuous subcutaneous therapy.
The primary efficacy variable is the mean change in time spent "OFF" from baseline (start of blinded treatment) to the end of a 12 weeks' double-blind treatment period based on patient diaries. Patients recorded their motor symptoms in half-hour blocks as OFF, ON without dyskinesia, ON without troublesome dyskinesia, or sleeping using the Hauser Parkinson's Disease home diary.
Key secondary Endpoints (tested hierarchically):
Other Endpoints:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
Drug: Apomorphine hydrochloride
Placebo: saline infusion
Drug: Placebo
Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
Also known as: Apo-go
Sodium chloride 9 mg/ml
Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population
The least squares mean reduction (improvement) in OFF time as reported by the patient using the Hauser Parkinson's disease home diary. Patients categorised their motor symptoms into OFF, ON with dyskinesia, ON without troublesome dyskinesia or sleeping using half hour blocks over 24 hours. Daily OFF time was computed from the average of valid motor diaries from the two days preceding each visit. Correct diary completion was evaluated during screening and observed by the investigator to ensure patients could categorise their motor symptoms correctly. A diary was considered valid if no more than 4 half-hour periods were either absent or duplicated. There were no invalid diaries at Baseline or Week 12.
Time frame: Baseline and 12 weeks
Mean Change in Daily Time Spent "ON Without Troublesome Dyskinesia" From Baseline to the End of the Double-blind Phase (Visit 10), Based on Patient Diaries Using MMRM mITT Population
The least squares mean change in "ON time without troublesome dyskinesia" as reported by the patient using the Hauser Parkinson's disease home diary. Each half hour of the day categorised as OFF, ON with dyskinesia, ON without troublesome dyskinesia or asleep. "ON time without troublesome dyskinesia" measures good ON time for a Parkinson's disease patient.
Time frame: Baseline and 12 weeks
Patient Global Impression of Change (PGIC), Using the mITT Population
PGIC is a self-administered questionnaire measuring personal general state of health on a 7-point rating scale. The 7 ordinal categories from which patients must choose are 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse. Results are presented as the % of patients who reported at least minimal improvement in general health status at week 12 compared to Baseline. A Wilcoxon range sum test was performed to test for treatment differences from baseline to end of 12 weeks' treatment period.
Time frame: Baseline and 12 weeks
Mean Change in Oral Levodopa Dose From Baseline to Visit 10 Using MMRM for the mITT Population
The least squares mean change in oral levodopa dose from Baseline to Visit 10 (week 12) was calculated excluding 3 centres who declined to participate in collecting the necessary details of PRN use of levodopa.
Time frame: Baseline and 12 weeks
Mean Change in Levodopa Equivalent Dose From Baseline to Visit 10 (Week 12) Using MMRM in the mITT Population
Levodopa equivalent dose is an indication of the burden of medication taken to control symptoms of Parkinson's disease with all medications other than levodopa itself being converted to a calculated levodopa dose using the methodology published by Tomlinson et al, 2010. The computation of LED excludes the study drug.
Time frame: Baseline and 12 weeks
| Milestone | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Started | 54 | 53 |
| Completed | 42 | 29 |
| Not completed | 12 | 24 |
| Withdrew: Adverse event | 6 | 0 |
| Withdrew: Lack of efficacy | 1 | 16 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Non-compliance with study drug | 1 | 3 |
| Withdrew: Minimum infusion rate poorly tolerated | 1 | 0 |
| Withdrew: Inconvenience of infusion system | 0 | 1 |
| Milestone | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Started | 84 | 0 |
| Completed | 59 | 0 |
| Not completed | 25 | 0 |
| Withdrew: Adverse event | 15 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 0 |
The least squares mean reduction (improvement) in OFF time as reported by the patient using the Hauser Parkinson's disease home diary. Patients categorised their motor symptoms into OFF, ON with dyskinesia, ON without troublesome dyskinesia or sleeping using half hour blocks over 24 hours. Daily OFF time was computed from the average of valid motor diaries from the two days preceding each visit. Correct diary completion was evaluated during screening and observed by the investigator to ensure patients could categorise their motor symptoms correctly. A diary was considered valid if no more than 4 half-hour periods were either absent or duplicated. There were no invalid diaries at Baseline or Week 12.
| Hours | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population | -2.61 (-3.43 to -1.80) | -0.75 (-1.66 to 0.16) |
The least squares mean change in "ON time without troublesome dyskinesia" as reported by the patient using the Hauser Parkinson's disease home diary. Each half hour of the day categorised as OFF, ON with dyskinesia, ON without troublesome dyskinesia or asleep. "ON time without troublesome dyskinesia" measures good ON time for a Parkinson's disease patient.
| Hours | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Mean Change in Daily Time Spent "ON Without Troublesome Dyskinesia" From Baseline to the End of the Double-blind Phase (Visit 10), Based on Patient Diaries Using MMRM mITT Population | 2.90 (2.07 to 3.73) | 0.85 (-0.09 to 1.78) |
PGIC is a self-administered questionnaire measuring personal general state of health on a 7-point rating scale. The 7 ordinal categories from which patients must choose are 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse. Results are presented as the % of patients who reported at least minimal improvement in general health status at week 12 compared to Baseline. A Wilcoxon range sum test was performed to test for treatment differences from baseline to end of 12 weeks' treatment period.
| % of participants | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Patient Global Impression of Change (PGIC), Using the mITT Population | 79.1 | 23.5 |
The least squares mean change in oral levodopa dose from Baseline to Visit 10 (week 12) was calculated excluding 3 centres who declined to participate in collecting the necessary details of PRN use of levodopa.
| mg | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Mean Change in Oral Levodopa Dose From Baseline to Visit 10 Using MMRM for the mITT Population | -242.09 (-346.58 to -137.61) | -76.46 (-185.17 to 32.25) |
Levodopa equivalent dose is an indication of the burden of medication taken to control symptoms of Parkinson's disease with all medications other than levodopa itself being converted to a calculated levodopa dose using the methodology published by Tomlinson et al, 2010. The computation of LED excludes the study drug.
| mg | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Mean Change in Levodopa Equivalent Dose From Baseline to Visit 10 (Week 12) Using MMRM in the mITT Population | -502.02 (-626.45 to -377.60) | -150.87 (-280.14 to -21.59) |
Collected over Adverse Events were collected during the double-blind and open label phases of the study. 98 patients were exposed to at least one dose of apomorphine with a cumulative person time of 4081 weeks of exposure. The range of exposure to apomorphine was 37-464 days (mean 397 days). In addition, 53 patients (44 of whom went onto apomorphine in the open label phase) were exposed to placebo treatment in the double blind phase with a maximum 12 weeks of exposure.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apomorphine Hydrochloride | 0/98 (0%) | 23/98 (23.5%) | 94/98 (95.9%) |
| Placebo | 0/53 (0%) | 2/53 (3.8%) | 30/53 (56.6%) |
| Event | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Infusion site cellulitisInfections and infestations | 2/98 | 0/53 |
| FallInjury, poisoning and procedural complications | 2/98 | 0/53 |
| DepressionPsychiatric disorders | 0/98 | 1/53 |
| ColitisGastrointestinal disorders | 1/98 | 1/53 |
| Confusional statePsychiatric disorders | 1/98 | 0/53 |
| LymphopeniaBlood and lymphatic system disorders | 1/98 | 0/53 |
| Myocardial infarctionCardiac disorders | 1/98 | 0/53 |
| Eosinophil count decreasedInvestigations | 1/98 | 0/53 |
| Haematocrit decreasedInvestigations | 1/98 | 0/53 |
| Blood disorderBlood and lymphatic system disorders | 1/98 | 0/53 |
| Event | Apomorphine Hydrochloride | Placebo |
|---|---|---|
| Infusion site noduleGeneral disorders | 46/98 | 0/53 |
| NauseaGastrointestinal disorders | 20/98 | 5/53 |
| SomnolenceNervous system disorders | 19/98 | 2/53 |
| Infusion site erythemaGeneral disorders | 15/98 | 2/53 |
| DyskinesiaNervous system disorders | 14/98 | 0/53 |
| InsomniaPsychiatric disorders | 13/98 | 1/53 |
| DizzinessNervous system disorders | 11/98 | 2/53 |
| HeadacheNervous system disorders | 10/98 | 2/53 |
| Infusion site haematomaGeneral disorders | 8/98 | 5/53 |
| VomitingGastrointestinal disorders | 8/98 | 2/53 |
Demographic Characteristics displayed for mITT population
| Age, Categorical(Participants) | Apomorphine Hydrochloride | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 28 | 54 |
| >=65 years | 27 | 24 | 51 |
| Age, Continuous(years) | Apomorphine Hydrochloride | Placebo | Total |
|---|---|---|---|
| Mean | 63.58 ± 9.32 | 63.00 ± 8.32 | 63.29 ± 8.80 |
| Sex: Female, Male(Participants) | Apomorphine Hydrochloride | Placebo | Total |
|---|---|---|---|
| Female | 19 | 20 | 39 |
| Male | 34 | 32 | 66 |
Plan to share: No
Ran from Mar 2014 to primary completion in Jun 2016, 27 months.
Results were first posted in Jul 2019, 3 years 1 month after primary completion.
Of 40 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 27 months is below that.
Counting every sponsor, half of 68 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apomorphine
Britannia Pharmaceuticals Ltd.